Biogen Pharma

how big is Biogen Pharma?

As of Jun 06, Biogen Pharmachem Industries Ltd has a market capitalization of 61.34 Cr, classifying it as a Micro Cap company, with recent net sales of 0.00 Cr and a net profit of -0.29 Cr. Shareholder's funds are valued at 56.52 Cr, and total assets amount to 56.82 Cr.

Market Cap: As of Jun 06, Biogen Pharmachem Industries Ltd has a market capitalization of 61.34 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the sum of Net Sales is 0.00 Cr, and the sum of Net Profit is -0.29 Cr. This data is presented on a Standalone basis.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period ending in Mar'24. The Shareholder's Funds are valued at 56.52 Cr, and the Total Assets amount to 56.82 Cr.

What does Biogen Pharma do?

Biogen Pharmachem Industries Ltd is a Micro Cap company engaged in trading shares, securities, and commodities within the Non Banking Financial Company (NBFC) sector. It was incorporated in 1995 and reported a net profit of 1 Cr for the quarter ending March 2025.

Overview:<BR>Biogen Pharmachem Industries Ltd is engaged in the business of trading in shares and securities, commodities, and other goods, operating within the Non Banking Financial Company (NBFC) industry and categorized as a Micro Cap.<BR><BR>History:<BR>The company was incorporated in July 1995 as Wellworth Overseas Limited and underwent several name changes, becoming Sun Techno Overseas Limited in August 2011 and finally Biogen Pharmachem Industries Limited on March 24, 2021. The latest reported quarter for sales and profit is March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: Rs 62 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 30<BR>Dividend Yield: 0.00%<BR>Debt Equity: -0.10<BR>Return on Equity: -0.51%<BR>Price to Book: 1.09<BR><BR>Contact Details:<BR>Address: Shop No 8 First Floor, Makers 1 Building Jawahar Road Rajkot Gujarat : 360001<BR>Phone: 91-79-27498832<BR>Email: suntechnooverseas@gmail.com<BR>Website: http://www.biogenpharma.shop

Who are in the management team of Biogen Pharma?

As of March 2022, the management team of Biogen Pharma includes Niraj Vaghela (Whole Time Director & CFO), Chandrakant Govingbhai Parmar, Manjulaben Parmar (both Independent Directors), Khushboo Khandelwal (Company Secretary & Compliance Officer), and Directors Harshadkumar Rathod, Narendrakumar Vaniya, and Komalben Chauhan. They oversee the company's operations and governance.

As of March 2022, the management team of Biogen Pharma includes the following individuals:<BR><BR>1. Niraj Vaghela - Whole Time Director & CFO<BR>2. Chandrakant Govingbhai Parmar - Independent Director<BR>3. Manjulaben Parmar - Independent Director<BR>4. Khushboo Khandelwal - Company Secretary & Compliance Officer<BR>5. Harshadkumar Rathod - Director<BR>6. Narendrakumar Vaniya - Director<BR>7. Komalben Chauhan - Director<BR><BR>These individuals are responsible for overseeing the company's operations and governance.

Has Biogen Pharma declared dividend?

No Dividend History Available

Who are the peers of the Biogen Pharma?

Biogen Pharma's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, and others. In terms of management risk, growth, and capital structure, Biogen Pharma has good ratings, with a 1-year return of -14.78%, better than Arnold Holdings but worse than BAMPSL Sec.

Peers: The peers of Biogen Pharma are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, ISL Consulting, Ladderup Finance, Arnold Holdings, BAMPSL Sec., and BSEL ALGO.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial. Good management risk is noted at Shriram Finance, and the rest have Below Average management risk, including ISL Consulting, Ladderup Finance, Arnold Holdings, Biogen Pharma, BAMPSL Sec., and BSEL ALGO. For Growth, Excellent growth is seen at Jio Financial, Arnold Holdings, and BAMPSL Sec., while Good growth is noted at Bajaj Finance and Cholaman.Inv.&Fn, with Average growth at Muthoot Finance and Shriram Finance, and the rest showing Below Average growth. In terms of Capital Structure, Excellent capital structure is found at Bajaj Finance, Jio Financial, Muthoot Finance, Shriram Finance, ISL Consulting, Ladderup Finance, Arnold Holdings, and BAMPSL Sec., while Good capital structure is noted at Biogen Pharma, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BAMPSL Sec. at 103.62%, while the lowest is Arnold Holdings at -47.98%. Biogen Pharma's 1-year return of -14.78% is better than Arnold Holdings but worse than BAMPSL Sec. Additionally, ISL Consulting, Arnold Holdings, and BSEL ALGO have negative six-month returns.

Is Biogen Pharma overvalued or undervalued?

As of May 26, 2025, Biogen Pharma is considered very expensive and overvalued due to a negative PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a low ROE of -0.51%, despite a 357.14% stock increase over five years, which underperformed against the Sensex's 7.62% return in the last year.

As of 26 May 2025, the valuation grade for Biogen Pharma has moved from risky to very expensive. The company is currently overvalued, as indicated by its PE ratio of -61.34, an EV to EBIT ratio of 55.88, and a Price to Book Value of 1.09. These ratios highlight significant concerns regarding profitability and valuation relative to its assets.<BR><BR>In comparison to its peers, Biogen Pharma's valuation stands out unfavorably; for instance, MMTC has a PE ratio of 119.39, while Elitecon International shows a PE of 131.08, both indicating a more favorable valuation in the market. Additionally, Biogen's return on equity (ROE) is at -0.51%, further emphasizing its struggles compared to competitors. While Biogen's stock has seen a notable increase of 357.14% over the past five years, it has underperformed against the Sensex in the last year, which returned 7.62%. This context reinforces the conclusion that Biogen Pharma is currently overvalued.

What is the technical trend for Biogen Pharma?

As of May 19, 2025, Biogen Pharma's trend is mildly bearish, indicated by daily moving averages and monthly MACD, while weekly indicators show mixed signals, leading to a moderate bearish outlook.

As of 19 May 2025, the technical trend for Biogen Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend and the monthly MACD showing a mildly bearish signal. Weekly indicators present a mixed picture with the MACD and KST both mildly bullish, while Bollinger Bands remain bearish. The lack of clear signals from the RSI further supports the neutral to mildly bearish outlook. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Who are the top shareholders of the Biogen Pharma?

The top shareholders of Biogen Pharma are individual investors, holding 47.04% of shares, with Rama Shiva Lease Finance Private Limited as the largest public shareholder at 9.31%. There are no institutional shareholders or pledged promoter holdings.

The top shareholders of Biogen Pharma include individual investors, who collectively hold 47.04% of the shares. The highest public shareholder is Rama Shiva Lease Finance Private Limited, which holds 9.31%. There are no institutional shareholders or mutual funds currently holding shares in the company, and there are no pledged promoter holdings.

How has been the historical performance of Biogen Pharma?

Biogen Pharma has experienced significant financial fluctuations, with net sales dropping to zero by March 2025 after a modest increase in previous years, while total expenditures rose sharply and profitability turned negative. Despite these challenges, shareholder funds increased, and cash flow from financing activities remained positive.

Answer:<BR>The historical performance of Biogen Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Biogen Pharma's net sales have remained at zero from March 2023 to March 2025, following a modest increase to 2.47 crore in March 2022 from 1.62 crore in March 2021. Other operating income peaked at 2.38 crore in March 2024 but dropped to zero in March 2025. Total operating income followed a similar trend, reaching 2.16 crore in March 2022 before declining to zero by March 2025. The company faced a total expenditure of 1.13 crore in March 2025, a significant increase from 0.45 crore in March 2024, while operating profit (PBDIT) turned negative at -0.29 crore in March 2025, contrasting with a profit of 1.93 crore in March 2024. Profit before tax also fell to -0.29 crore in March 2025 from 1.93 crore in the previous year. The company's reserves have been negative, reaching -9.03 crore in March 2025, and shareholder's funds increased to 91.93 crore in March 2025 from 56.52 crore in March 2024. Cash flow from operating activities was negative at -1.00 crore in March 2025, while cash flow from financing activities showed a positive inflow of 35.00 crore. Overall, Biogen Pharma's financial performance has been marked by instability, with recent years showing a decline in sales and profitability, despite an increase in cash reserves.

When is the next results date for Biogen Pharmachem Industries Ltd?

The next results date for Biogen Pharmachem Industries Ltd is 11 February 2026.

The next results date for Biogen Pharmachem Industries Ltd is scheduled for 11 February 2026.

Are Biogen Pharmachem Industries Ltd latest results good or bad?

Biogen Pharmachem Industries Ltd's latest results show a slight profit turnaround, with a net profit of ₹0.46 crores in Q3 FY26, but this was mainly due to non-operating income and zero net sales for seven quarters. Overall, the financial health remains concerning, with low return on equity and significant stock underperformance, indicating caution for potential investors.

Biogen Pharmachem Industries Ltd's latest results present a mixed picture. In Q3 FY26, the company reported a net profit of ₹0.46 crores, which is a positive turnaround from a loss of ₹0.49 crores in the previous quarter and a loss of ₹0.31 crores in the same quarter last year. This indicates some improvement in profitability, but it's important to note that this profit was largely driven by other income rather than operational revenue, as the company has reported zero net sales for the past seven quarters.<BR><BR>While the nine-month net profit of ₹1.31 crores shows a significant improvement from a loss of ₹1.47 crores in the same period last year, the overall financial health raises concerns. The company's return on equity (ROE) is quite low at 1.74%, and it has been struggling with consistent operational performance. The absence of revenue generation and reliance on non-operating income are critical red flags.<BR><BR>Additionally, the stock has severely underperformed over the past year, declining by 34.91%, which is significantly worse than the broader market performance. The valuation metrics also suggest that the stock is expensive relative to its fundamentals, with a P/E ratio of 36.21 times trailing earnings, which is above the industry average.<BR><BR>In summary, while there are some positive signs in terms of profitability, the lack of operational revenue and ongoing financial challenges suggest that the overall results are not strong enough to indicate a solid recovery. Caution is advised for potential investors.

Should I buy, sell or hold Biogen Pharmachem Industries Ltd?

Why is Biogen Pharmachem Industries Ltd falling/rising?

As of 23-Mar, Biogen Pharmachem Industries Ltd's stock price is declining, currently at 0.53, with significant underperformance compared to the Sensex. Weak fundamentals, including operating losses and low return on equity, alongside a bearish trend in stock performance, contribute to the ongoing decline.

As of 23-Mar, Biogen Pharmachem Industries Ltd's stock price is falling, currently at 0.53, reflecting a decrease of 0.01 or 1.85%. The stock has underperformed significantly compared to the benchmark Sensex, with a one-week decline of 7.02% and a one-month decline of 23.19%. Over the past year, the stock has experienced a substantial drop of 47.52%, while the Sensex has only decreased by 5.47%.<BR><BR>Today's performance indicates that the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Although there was a rise in delivery volume by 52.5% on March 20, indicating increased investor participation, this has not translated into a positive price movement.<BR><BR>The company's fundamentals are weak, characterized by operating losses and a poor ability to service its debt, as evidenced by an EBIT to Interest ratio of 0.81. Additionally, the company has shown poor long-term growth, with an annual operating profit growth rate of only 11.46% over the last five years. The stock's return on equity (ROE) is low at 2.5, and it is considered to have a very expensive valuation with a price-to-book value of 0.5. Despite a significant increase in profits of 322% over the past year, the stock's performance has not reflected this growth, resulting in a PEG ratio of 0.1, indicating that the stock is trading at a discount compared to its peers' average historical valuations. <BR><BR>Overall, the combination of weak fundamentals, poor performance relative to the market, and negative price movements contribute to the ongoing decline in Biogen Pharmachem Industries Ltd's stock price.

Why is Biogen Pharmachem Industries Ltd falling/rising?

As of 24-Mar, Biogen Pharmachem Industries Ltd's stock price is at 0.53, unchanged from the previous session, with significant declines of 7.02% over the past week and 22.06% over the past month. The stock is underperforming the market and is considered a strong sell due to weak financial fundamentals and a poor ability to service debt.

As of 24-Mar, Biogen Pharmachem Industries Ltd's stock price is currently at 0.53, showing no change from the previous trading session. The stock has been underperforming significantly, with a decline of 7.02% over the past week and 22.06% over the past month. Year-to-date, the stock has fallen by 23.19%, and over the past year, it has decreased by 47.52%. <BR><BR>The stock's performance is notably weaker compared to the benchmark Sensex, which has only declined by 2.63% in the last week and 9.92% in the last month. Additionally, Biogen Pharma is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. <BR><BR>Despite a rise in delivery volume by 17.01% against the 5-day average, the overall sentiment remains negative due to the company's operating losses and weak long-term fundamental strength. The company's ability to service its debt is also concerning, with a poor EBIT to Interest ratio of 0.81. Furthermore, the stock is considered a strong sell due to its very expensive valuation, reflected in a low return on equity (ROE) of 2.5 and a price-to-book value of 0.5. <BR><BR>In summary, the combination of poor performance metrics, weak financial fundamentals, and underperformance relative to the market are contributing to the decline in Biogen Pharmachem Industries Ltd's stock price.

Why is Biogen Pharmachem Industries Ltd falling/rising?

As of 25-Mar, Biogen Pharmachem Industries Ltd's stock price is at 0.52, reflecting a significant decline of 48.51% over the past year, with persistent underperformance compared to the Sensex. The stock is near its 52-week low and shows a downward trend with decreased investor participation.

As of 25-Mar, Biogen Pharmachem Industries Ltd's stock price is falling, currently at 0.52, which reflects a change of -0.01 or -1.89%. The stock has underperformed significantly over various periods, with a 1-week decline of 7.14% compared to a 1.87% drop in the Sensex, and a 1-month decrease of 23.53% against an 8.51% decline in the benchmark index. Year-to-date, the stock has fallen by 24.64%, while the Sensex has decreased by 11.67%. Over the past year, Biogen's stock has plummeted by 48.51%, contrasting sharply with the Sensex's modest decline of 3.52%.<BR><BR>Additionally, the stock is trading close to its 52-week low, being only 3.85% away from a low of Rs 0.5. It is also trading lower than its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This indicates a persistent downward trend. Furthermore, there has been a notable decrease in investor participation, with delivery volume falling by 27.91% against the 5-day average. Despite the sector's overall gain of 2.46%, Biogen's performance has lagged behind, contributing to the continued decline in its stock price.

Which are the latest news on Biogen Pharma?